Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, February 3rd, Michael Alexander Smith sold 640 shares of Insmed stock. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80.
• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $241,968.68.

Insmed Trading Down 1.5%

NASDAQ INSM opened at $162.43 on Friday. The firm has a market cap of $35.01 billion, a PE ratio of -25.34 and a beta of 1.10. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The stock has a 50-day moving average of $150.18 and a 200-day moving average of $166.38. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed’s revenue was up 152.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.32) earnings per share. As a group, sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hsbc Holdings PLC increased its position in shares of Insmed by 8,052.6% during the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock valued at $21,493,000 after buying an additional 121,755 shares during the period. Rockefeller Capital Management L.P. boosted its position in Insmed by 88.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company’s stock valued at $2,920,000 after acquiring an additional 7,863 shares in the last quarter. Corient Private Wealth LLC boosted its position in Insmed by 34.1% during the 4th quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company’s stock valued at $3,631,000 after acquiring an additional 5,305 shares in the last quarter. Keenan LLC purchased a new position in shares of Insmed during the 4th quarter worth approximately $369,000. Finally, Reflection Asset Management purchased a new position in shares of Insmed during the 4th quarter worth approximately $30,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Truist Financial set a $205.00 price target on shares of Insmed in a research report on Monday, January 12th. Leerink Partners upped their price objective on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. Wolfe Research set a $167.00 target price on shares of Insmed and gave the stock an “outperform” rating in a report on Thursday, December 18th. Citigroup reissued an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, The Goldman Sachs Group upped their price target on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $212.67.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Barclays raised its price target from $231 to $237 and kept an “overweight” rating, implying roughly ~46% upside vs the current price — a clear catalyst for buy-side interest. Barclays price-target hike (Benzinga)
• Positive Sentiment: Morgan Stanley also upgraded Insmed to Overweight, reinforcing institutional bullishness and supporting near-term momentum. Morgan Stanley upgrade (American Banking News)
• Positive Sentiment: Analyst and market commentary highlights Insmed’s strong Brinsupri launch and attractive pipeline (TPIP for PAH/PH-ILD), arguing the pipeline is beginning to justify the company’s valuation — a bullish medium-term thesis. Insmed: The Pipeline Is Catching Up To The Valuation (Seeking Alpha)
• Positive Sentiment: Options-focused coverage notes bullish activity after the Barclays lift, indicating elevated speculative interest that can amplify upside moves. Options Bulls Could Be Right About This Pharma Stock (Schaeffer’s)
• Neutral Sentiment: News pieces reporting the analyst upgrades and the intraday price pop summarize the firm reaction but add little new fundamental information. Insmed Stock Price Up on Analyst Upgrade (American Banking News)
• Negative Sentiment: Insider Michael Alexander Smith sold 19,638 shares (~27% reduction in his post-sale position), a transaction worth roughly $3.0M at ~$151/share — insider selling can be viewed as a near-term negative for sentiment. SEC Filing: Insider Sale
• Negative Sentiment: Coverage on proposed MFN pricing in the U.S. suggests it could delay European drug launches broadly — a policy risk that could slow Insmed’s international rollouts and damp future revenue upside. Trump’s MFN Pricing Expected To Delay More European Drug Launches (BioSpace)

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.